Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/08/2021 | 04:31pm EST

Aprea Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 9.45 million compared to USD 12.32 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.58 a year ago. For the nine months, net loss was USD 29.37 million compared to USD 38.09 million a year ago. Basic loss per share from continuing operations was USD 1.39 compared to USD 1.8 a year ago.


ę S&P Capital IQ 2021
All news about APREA THERAPEUTICS, INC.
01/13APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
01/06Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on T..
AQ
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Biotechnology Index
CI
2021Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant..
AQ
2021Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azaci..
AQ
2021Aprea Therapeutics, Inc. Announces Updated Results from Its Phase 2 Trial Evaluating Ep..
CI
2021APREA THERAPEUTICS : Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Ma..
PU
2021APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Aprea Therapeutics Says FDA Has Removed Its Clinical Hold on Study of Eprenetapopt for ..
MT
2021APREA THERAPEUTICS : FDA Lifts Hold on Eprenetapopt Study in Lymphoid Malignancies
DJ
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -38,2 M - -
Net cash 2021 55,1 M - -
P/E ratio 2021 -1,28x
Yield 2021 -
Capitalization 49,4 M 49,4 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 11
Free-Float -
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 2,30 $
Average target price 4,33 $
Spread / Average Target 88,4%
EPS Revisions
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars AbrahmsÚn Chief Scientific Officer & Senior Vice President
Bernd Robert Seizinger Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-19.86%49
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508